Exosomes are 30–150 nm vesicles that transport proteins, lipids, and genetic material between cells. Research shows they influence cellular communication, immune responses, and drug delivery.
Vybion developed vectorized Intrabodies using AAV to deliver functional antibody fragments in scFv format. The company holds FDA Orphan Drug Designation for INT41 to treat Huntington’s disease, a fatal neurodegenerative condition.
Vybion develops Intrabodies for neurodegenerative diseases using scFv fragments to target protein aggregation, gene dysregulation, and toxic protein turnover.
Vybion (formerly Viral Therapeutics, Inc.) rebrands as a biopharmaceutical developer specializing in Protein Evolution Tools. The company leverages over a decade of experience and a proprietary platform to accelerate drug development, improve production yields, and enhance bioactivity for both internal and external projects.